LUND, Sweden, October 17, 2022 /PRNewswire/ — Immunovia AB IMNOV (Stockholm: IMMNOV) announced today that it is entering into a strategic partnership with Proteomedix to leverage their extensive joint development experience in diagnostic technologies for cancer detection. This will enable Immunovia to increase R&D productivity as the company continues to ramp up its commercial development in the US.

The partnership between Immunovia and Proteomedix leverages the companies’ complementary R&D capabilities and enhances their R&D efforts. With this partnership, Immunovia will gain a more flexible R&D organization, increase its R&D productivity and focus internal resources on commercial build-out, further accelerating the adoption of IMMray™ PanCan-d. The partnership benefits from the combined expertise of two leading innovators in proteomics-based diagnostics who have both brought innovative oncology tests to market, Immunovia with IMMray™ PanCan-d in the US and Proteomedix with Proclarix^® in Europe.

Proteomedix, a Switzerland-based company, was founded in 2010 as a spin-off from ETH Zurich to bring together the expertise of a multidisciplinary group of world-leading scientists and clinicians in the field of proteomics-based diagnostics. The company is focused on research and development, drawing on a network of clinicians, IVD experts, laboratories and marketers. Proteomedix has developed a blood-based prostate cancer test using Proteomics technology that measures cancer-associated proteins using highly reproducible immunoassays.

“We are very pleased to enter into this partnership with Immunovia, an early commercial company like us with an innovative diagnostic test in oncology. This partnership enables both companies to make critical strides forward faster, leveraging our combined expertise to increase R&D efficiencies. For Proteomedix , this partnership demonstrates how our expertise in developing biomarker assays can be applied beyond the prostate…